Your session is about to expire
← Back to Search
Mirvetuximab Soravtansine + Gemcitabine Hydrochloride for Ovarian, Breast, Fallopian Tube, Peritoneal, and Uterine Cancer
Study Summary
This trial is testing the side effects and best dose of two drugs, mirvetuximab soravtansine and gemcitabine hydrochloride, in treating patients with cancer that has come back. Mirvetuximab soravtansine is a monoclonal antibody linked to a chemotherapy drug, and gemcitabine hydrochloride is a chemotherapy drug.
- Breast Cancer
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Carcinoma
- Uterine Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Treatment (IMGN853, gemcitabine hydrochloride)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What additional research has been conducted regarding Pharmacological Study?
"Presently, there are 135 trials undergoing Phase 3 and 452 ongoing studies related to Pharmacological Study. Of the 24860 locations with clinical research on this subject, many of them exist in Woolloongabba, Queensland."
What risks accompany Pharmacological Study for participants?
"The safety rating for this pharmacological study is 1 due to it being a Phase 1 trial, which presents minimal evidence in regards to both efficacy and security."
What is the sample size of participants for this research program?
"Unfortunately, this research project is no longer accepting candidates; the trial was initially posted in March 2017 and last updated on June 7th 2022. Fortunately, if you look for other opportunities there are currently 5386 studies that target relapse cases as well as 452 trials looking to recruit participants into a Pharmacological Study."
Are there any opportunities for enrolment in this clinical research?
"Unfortunately, this trial has ceased to recruit patients. Initially posted in March 2017 and recently modified on June 7th 2022, it is no longer an option for participation. However, there are currently 5386 studies involving relapse that remain open as well as 452 Pharmacological Studies still accepting applicants."
In what ways is Pharmacological Study typically employed?
"Pharmacological Study is an effective intervention for small cell lung cancer (SCLC), head and neck carcinoma, as well as locally advanced pancreatic adenocarcinoma."
Share this study with friends
Copy Link
Messenger